Figure 5.

First‐line management of HIV–PEL. Purple: algorithm title; blue: systemic anticancer therapy or their combination; turquoise: non‐systemic anticancer therapies or combination of treatment modalities; white: other management and non‐treatment aspects; dashed lines: optional therapy. ASCT, autologous stem‐cell transplantation; CD, cluster of differentiation; CHOP, cyclophosphamide–doxorubicin–vincristine–prednisone; DA, dose‐adjusted; EMA, European Medicines Agency; EPOCH, etoposide–prednisone–vincristine–cyclophosphamide–doxorubicin; FDA, Food and Drug Administration; HDCT, high‐dose chemotherapy; HIV, human immunodeficiency virus; HIV–PEL, human immunodeficiency virus‐associated primary effusion lymphoma; PEL, primary effusion lymphoma. ^aNot EMA or FDA approved for the treatment of PEL.